Maynard Um
-
-
-
-
-
-
-
Insulet reports positive trial data for next-generation diabetes systems
-
-
-
-
-
-
-
RBC sees over 80% upside to its price target for this medical stock
-
-
-
-
-
-
-
Insulet begins pivotal trial for fully closed-loop diabetes system
-
-
-
-
-
-
-
Insulet Corporation (PODD) PT Lowered to $330 at Bernstein
-
-
-
-
-
-
-
Barclays Downgrades Insulet Corporation (PODD) to Underweight
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Insulet Corporation (PODD)
-
-
-
-
-
-
-
Insulet Corporation (PODD) PT Raised to $412 at Truist Securities
-
417,303 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

